Learn About Hajdu-Cheney Syndrome

What is the definition of Hajdu-Cheney Syndrome?

Hajdu-Cheney syndrome is a rare disorder that can affect many parts of the body, particularly the bones. Bone loss from the tips of the fingers and toes (acroosteolysis) is a characteristic feature of the condition. The fingers and toes may appear short and rounded, and they may become shorter over time as the bone continues to break down. In people with Hajdu-Cheney syndrome, the fingers are more likely to be affected than the toes. Bone loss in the fingers can interfere with fine motor skills, such as picking up small objects.

What are the causes of Hajdu-Cheney Syndrome?

Hajdu-Cheney syndrome is associated with variants (also called mutations) in the NOTCH2 gene. This gene provides instructions for making a receptor protein. Other proteins, called ligands, can fit into specific sites on receptor proteins, like a key into a lock. When a ligand binds to the NOTCH2 receptor protein, it triggers a signaling pathway called the NOTCH2 signaling pathway. NOTCH2 signaling is important for the early development of bones and for bone remodeling, a normal process in which old bone is removed and new bone is created to replace it. NOTCH2 signaling also appears to be involved in the development of the heart, kidneys, teeth, and other parts of the body.

How prevalent is Hajdu-Cheney Syndrome?

Although Hajdu-Cheney syndrome is a rare disease, its exact prevalence is unknown. Fewer than 100 affected individuals have been described in the medical literature.

Is Hajdu-Cheney Syndrome an inherited disorder?

Hajdu-Cheney syndrome is inherited in an autosomal dominant pattern, which means one copy of the altered gene in each cell is sufficient to cause the disorder. Many cases of this condition result from a new (de novo) variant in the gene that occurs during the formation of reproductive cells (eggs or sperm) in an affected individual's parent or during early embryonic development. These affected individuals typically have no history of the disorder in their family.

Who are the top Hajdu-Cheney Syndrome Local Doctors?
Elite in Hajdu-Cheney Syndrome
Elite in Hajdu-Cheney Syndrome

Dysautonomia Center Llp

530 1st Ave, Suite 9q, 
New York, NY 
Languages Spoken:
English
Offers Telehealth

Horacio Kaufmann is a Neurologist in New York, New York. Dr. Kaufmann is rated as an Elite provider by MediFind in the treatment of Hajdu-Cheney Syndrome. His top areas of expertise are Familial Dysautonomia, Hereditary Sensory and Autonomic Neuropathy Type 2, Hajdu-Cheney Syndrome, and Orthostatic Hypotension.

Elite in Hajdu-Cheney Syndrome
Elite in Hajdu-Cheney Syndrome
Zurich, ZH, CH 

Thorsten Hornemann practices in Zurich, Switzerland. Mr. Hornemann is rated as an Elite expert by MediFind in the treatment of Hajdu-Cheney Syndrome. His top areas of expertise are Hereditary Sensory Neuropathy Type 1 (HSN1), Hereditary Sensory and Autonomic Neuropathy Type 2, Hajdu-Cheney Syndrome, Anhidrosis, and Gastric Bypass.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Hajdu-Cheney Syndrome
Elite in Hajdu-Cheney Syndrome
Aachen, NW, DE 

Ingo Kurth practices in Aachen, Germany. Mr. Kurth is rated as an Elite expert by MediFind in the treatment of Hajdu-Cheney Syndrome. His top areas of expertise are Hajdu-Cheney Syndrome, Hereditary Sensory and Autonomic Neuropathy Type 2, Hereditary Sensory Neuropathy Type 1 (HSN1), Anhidrosis, and Bone Marrow Transplant.

What are the latest Hajdu-Cheney Syndrome Clinical Trials?
A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors

Summary: This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more about the side effects of ART0380 alone and in combination with gemcitabine or irinotecan * Learn mo...

Match to trials
Find the right clinical trials for you in under a minute
Get started
The Cancer of the Pancreas Screening-5 CAPS5)Study

Summary: Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.

Who are the sources who wrote this article ?

Published Date: December 15, 2025
Published By: National Institutes of Health